CHOP protocol-cyclophosphamide/doxorubicin/prednisone/vincristine

Known as: CTX/DOX/PRED/VCR, ACOP, cyclophosphamide, doxorubicin, prednisone, and vincristine protocol 
 
National Institutes of Health

Related topics

Related topics

14 relations

Broader (5)

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideCyclophosphamide/Doxorubicin/Etoposide/Prednisone/VincristineDoxorubicin
(More)
CDE protocol-cyclophosphamide/doxorubicin/etoposideCHOP regimenDoxorubicin HydrochloridePrednisone
(More)

Narrower (2)

CHOP-14 protocolCHOP-21 protocol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non…
BACKGROUND Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International…
BACKGROUND The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
BACKGROUND The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Crizotinib in anaplastic large-cell lymphoma.
To the Editor: Crizotinib, an inhibitor of the anaplastic lymphoma kinase (ALK) tyrosine kinase, is active in non–small-cell lung… (More)
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
PURPOSE Our previous phase II trial for treating human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94…
The purpose of this study is to compare our standard chemotherapy regimen (CHVP [cyclophosphamide, doxorubicin, teniposide, and… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized…
We evaluated the role of rituximab (R) both in remission induction and maintenance treatment of relapsed/resistant follicular… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
PURPOSE Long-term follow-up with updated time to disease progression (TTP) and duration of response (DR) data are presented from… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
In diffuse large B-cell lymphoma (DLBCL), the combination of rituximab and CHOP (cyclophosphamide, doxorubicine, vincristine… (More)
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
CopA: An Escherichia coli Cu(I)-translocating P-type ATPase.
The copA gene product, a putative copper-translocating P-type ATPase, has been shown to be involved in copper resistance in… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?